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protein acceptors passing through the ER, or under cir- uct is released, the active site for transfer would now
be accessible for dolichyl oligosaccharide binding tocumstances where the N-glycosylation consensus se-
quence (Asn-X-Ser/Thre motif) is not glycosylated. Al- incoming peptide, ensuring a continuous and efficient
supply of N-linked glycosylated protein, as specified bythough this site is consistently glycosylated in many
individual proteins, the local protein environment may the protein sequence.
The Imperiali group also shows that the use of productdictate incomplete glycosylation. Currently, a clear un-
derstanding of this mechanism is lacking, but in either mimics of OT reactants allows further definition of the
mechanism of action of this enigmatic enzyme and dem-case, the resultant dolichyl oligosaccharide is cleaved
and free oligosaccharide is generated. This oligosac- onstrates the exquisite means that enzymes use to con-
trol biologically significant processes in eukaryotic cells.charide is eventually cleared from the lumen of the ER
to the lysosome, after limited digestion with cytosolic
mannosidases [9]. Terry D. Butters
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of Glycopeptide Antibiotics including methicillin-resistant Staphylococcus aureus
(MRSA) [2, 3]. With the emergence of vancomycin-resis-
tant enterococci (VRE) and S. aureus (VRSA), the devel-
opment of new derivatives of vancomycin [4] and the
The glycosyltransferases GtfE and GtfD from the van- development of other antibiotics with new modes of
comycin producer Amycolatopsis orientalis have pro- action (e.g., daptomycin [5]) are important for the treat-
miscuous substrate and NDP-sugar specificities. They ment of life-threatening gram-positive infections.
have been used to generate novel glycopeptide antibi- Like vancomycin, chloroeremomycin is produced by
otics containing the heptapeptide scaffolds of vanco- a strain of A. orientalis [6]. Chloroeremomycin differs
mycin and teichoplanin [1]. from vancomycin in its pattern of glycosylation. Vanco-
mycin has the disaccacharide D-glucose-L-vancosamine
The glycopeptide antibiotics vancomycin and teico- attached to the phenolic group of hydroxyphenylglycine
planin are secondary metabolites produced by soil acti- at amino acid 4 of the heptapeptide. Chloeremomycin
has the disaccharide D-glucose-L-4-epi-vancosaminenomycetes, A. orientalis and Actinoplanes teichomyceti-
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attached at the same position, but also has a second cone using TDP- or UDP-D-glucose as sugar donors.
L-4-epi-vancosamine attached to the 2-hydroxyl group The GtfE enzyme (but not GtfB) could also glycosylate
of 2-hydroxytyrosine at amino acid 6. The difference A47934, an antibiotic with a teicoplanin-like heptapep-
in glycosylation patterns apparently accounts for the tide, but lacking sugar residues. Insertion of the gtfE
increased activity of chloroeremomycin against VRE [4]. gene into the chromosome of S. toyocaensis under the
Oritavancin (LY333328) is an N-alkyl derivative of chlo- control of the ermEp* promoter caused the production
roeremomycin containing a p-chloro-biphenyl group of novel antibiotic glucosyl-A47934.
attached to the amino group of the disaccharide D-glu- Building on these observations, Losey et al. [20]
cose-4-epi-vancosamine. This compound has substan- cloned, expressed, and purified the products of the gtfB
tially improved antibacterial activity against VRE [4, 7]. and gtfC genes from the chloroeremomycin producer
This type of modification apparently shifts the mecha- and the gtfD and gtfE genes from the vancomycin pro-
nism of action of glycopeptides from being predomi- ducer. They confirmed that the GtfE glucosyltransferase
nantly transpeptidase inhibitors to being predominantly had relaxed substrate specificity. They further demon-
transglycosylase inhibitors [8, 9], thus reducing the influ- strated that GtfC and GtfD enzymes were proficient in
ence of the D-ala-D-lac stem peptide terminus in VanR attaching epi-vancosamine to the vancomycin psuedo-
strains. aglycone and to the glucosylated teicoplanin aglycone
The heptapeptide backbones of glycopeptides re- when UDP--L-4-epi-vancosamine was used as the
lated to vancomycin and teicoplanin are assembled by sugar donor. Importantly, the GtfD enzyme, which nor-
giant multidomain multisubunit nonribosomal peptide mally adds vancosamine to the vancomycin pseudo-
synthetases (NRPSs) [10, 11]. NRPSs and polyketide aglycone, was able to catalyze the reaction using an
synthases (PKSs) are involved in the biosynthesis of a unnatural accepter substrate and an unnatural UDP-
vast array of secondary metabolites produced by Strep- sugar donor.
tomyces species and other actinomycetes. These versa- In the study published in this issue of Chemistry &
tile enzymes use simple fatty acid (PKSs) or amino acid Biology, Losey et al. [1] have used a chemienzymatic
(NRPSs) building blocks to synthesize very complex approach to synthesize a number of NDP-glucose ana-
scaffolds that can be further modified by “tailoring” en-
logs, using a promiscuous thymidylyltransferase [21,
zymes (e.g., hydroxylases, methyltransferases, halo-
22]. The generation of NDP-sugar substrates has limited
genases/haloperoxidases, and glycosyltransferases).
the in vitro exploration of glycosyltransferases involved
Many gene clusters for polyketide and peptide biosyn-
in secondary metabolism in the past. They demon-thesis have been cloned and analyzed, and advance-
strated that the GtfE enzyme from the vancomycin pro-ments in methodologies for the genetic manipulation of
ducer could use both UDP- and TDP-glucose analogs,actinomycetes have paved the way to modify the genetic
including various deoxyglucose analogs and analogsblueprints of PKS pathways to carry out “combinatorial
with amino groups at the 2, 3, 4, or 6 position, as sugarbiosynthesis” of the polyketide core structures [12, 13].
donors for glycosylation of the vancomycin and tei-The modular organization of the NRPS genes, which is
choplanin aglycones. Remarkably, the GtfD enzyme,similar to the modular organization of type I PKS genes,
which normally adds vancosamine to the glucose moietyalso suggests that combinatorial biosynthesis of novel
of the vancomycin pseudoaglycone, was able to addpeptides will be extended to actinomycetes. Examples
4-epi-vancosamine to each of the derivatives generatedof molecular genetic manipulation of NRPS genes in
by the GtfE enzyme (except those with 2-deoxy substitu-Bacillus have been reported [14].
tions, the site of glycosylation). This indicates that bothMany polyketides and NRPS-derived peptides (such
enzymes have relaxed specificity for acceptor substrateas vancomycin and chloroeremomycin) are glycosyl-
and NDP-sugar cofactor. The generation of several de-ated, primarily by 6-deoxysugars. Over 100 different
rivatives of vancomycin having two amino sugars, withdeoxyhexoses have been identified in secondary metab-
the amino group of the first sugar distributed at threeolites [15]. It is not surprising, therefore, that sugar resi-
different positions, provides novel scaffolds for furtherdues are often required for the exquisite biological activ-
N-alkylation to generate analogs related to oritavancin.ities of many secondary metabolites [16]. This appears
This is the first extensive demonstration of the feasibil-to be true for glycopeptides: some nonglycosylated gly-
ity to carry out combinatorial glycosylation of peptidescopeptides have excellent in vitro antibacterial activities
using promiscuous glycosyltransferases. Coupled withbut lack in vivo efficacy [17]. Many genes for deoxyhex-
ose biosynthesis have been cloned and sequenced, and the recent advances on combinatorial glycosylation of
a number of them are organized in discrete clusters that polyketides, this adds a new dimension to the possibili-
can be genetically manipulated [18]. Some glycosyl- ties for combinatorial biosynthesis to generate mole-
transferases have relatively broad substrate specificities cules with important pharmacological properties not
for type I or type II polyketides and can be used to readily obtainable by chemical syntheses. These in turn
generate novel structures not amenable to chemical can be further modified chemically to generate candi-
syntheses [18, 19]. dates for clinical development.
Solenberg et al. [6] cloned three glycosyltransferase
genes from the chloroeremomycin producer and two
from the vancomycin producer. They showed by expres-
Richard H. Baltzsion studies in E. coli that the glucosyltransferase en-
Natural Products Researchzymes encoded by the gtfE gene from the vancomycin
Cubist Pharmaceuticalsproducer, and the gtfB gene from the chloroeremomycin
producer, could attach glucose to the vancomycin agly- Lexington, Massachusetts 02421
Chemistry & Biology
1270
Selected Reading B.K., Walsh, C.T., and Wright, G.D. (2002). Proc. Natl. Acad. Sci.
USA 99, 8962–8967.
1. Losey, H.C., Jiang, J., Biggens, J.B., Oberthur, M., Ye, J.-Y., 12. Hopwood, D.A. (1997). Chem. Rev. 97, 2465–2497.
Dong, S.D., Kahne, D., Thorson, J.S., and Walsh, C.T. (2002). 13. Katz, L. (1997). Chem. Rev. 97, 2557–2575.
Chem. Biol. 9, 1305–1314. 14. Marahiel, M., Stachelhaus, T., and Mootz, H.D. (1997). Chem.
2. Wood, M.J. (1996). J. Antimicrob. Chemother. 37, 209–222. Rev. 97, 2651–2673.
3. Zeckel, M.L. (1997). J. Chemother. 9, 311–331. 15. Piepersberg, W., and Distler, J. (1997). In Biotechnology, 2nd ed.,
4. Cooper, R.D., Snyder, N.J., Zweifel, M.J., Staszak, M.A., Wilkie, Volume 7, H.-J. Rehm, G. Reed, A. Pu¨hler, and P. Stadler, eds.
S.C., Nicas, T.I., Mullen, D.L., Butler, T.F., Rodriquez, M.J., Huff, (Weinheim: Wiley-VCH), pp. 399–488.
B.E., et al. (1996). J. Antibiot. 49, 575–581. 16. Weymouth-Wilson, A.C. (1997). Nat. Prod. Rep. 14, 99–110.
5. Tally, F.P., Zeckel, M., Wasilewski, M.M., Carini, C., Berman, 17. Lancini, G.C., and Cavalleri, B. (1990). In Biochemistry of Peptide
C.L., Drusano, G.L., and Oleson, F.B. (1999). Expert Opin. In- Antibiotics, H. Kleinkauf and H. Von Du¨hren, eds. (Berlin: Walter
vestig. Drugs 8, 1223–1238.
de Gruyter), pp. 159–178.
6. Solenberg, P.J., Matsushima, P., Stack, D.R., Wilkie, S.C.,
18. Mendez, C., and Salas, J.A. (2001). Trends Biotechnol. 19,Thompson, R.C., and Baltz, R.H. (1997). Chem. Biol. 4, 195–202.
449–456.7. Barrett, J.F. (2001). Curr. Opin. Investig. Drugs 2, 1039–1044.
19. Tang, L., and McDaniel, R. (2001). Chem. Biol. 8, 547–555.8. Ge, M., Chen, Z., Onishi, H.R., Kohler, J., Silver, L.L., Kerns, R.,
20. Losey, H.C., Peczuh, M.W., Chen, Z., Eggert, U.S., Dong, S.D.,Fukuzawa, S., Thompson, C., and Kahne, D. (1999). Science
Pelczer, I., Kahne, D., and Walsh, C.T. (2001). Biochemistry 40,284, 507–510.
4745–4755.9. Eggert, U.S., Ruiz, N., Falcone, B.V., Branstrom, A.A., Goldman,
21. Jiang, J., Biggens, J.B., and Thorson, J.S. (2001). Angew. Chem.R.C., Silhavy, T.J., and Kahne, D. (2001). Science 294, 361–364.
Int. Ed. Engl. 40, 1502–1505.10. van Wageningen, A.M., Kirkpatrick, P.N., Williams, D.H., Harris,
22. Barton, W.A., Lesniak, J., Biggens, J.B., Jeffrey, P.D., Jiang, J.,B.R., Kershaw, J.K., Lennard, N.J., Jones, M., Jones, S.J., and
Rajashankar, K.R., Thorson, J.S., and Nikolov, D.B. (2001). Nat.Solenberg, P.J. (1998). Chem. Biol. 5, 155–162.
11. Pootoolal, J., Thomas, M.G., Marshall, C.G., Neu, J.M., Hubbard, Struct. Biol. 8, 545–551.
only ten of these have been determined, of which seven
are of the mechanistically predictable inverting trans-
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One Step Closer to a Sweet
Conclusion ferases. A key distinction from the glycosidases is that
only two fundamental protein folds (termed GT-A and
GT-B; Figure 1) have been uncovered for transferases,
and sequence analysis has suggested that this situationOtsA is required for the biosynthesis of trehalose, a
will hold true for a large number of the as yet structurallynonreducing disaccharide that is important for bacte-
uncharacterized families [2]. The GT-A fold family com-rial survival and stress responses. In this issue of
prises a single Rossman fold domain and has been iden-Chemistry & Biology, the structure of OtsA is uncov-
tified in the structures of both inverting and retainingered and reveals an unexpected relationship between
transferases (Figure 1). Enzymes of the GT-B fold havethe enzyme’s structure and function.
a twin Rossman fold structure, and up to this point all
those identified have been inverting transferases, possi-The synthesis and degradation of glycosidic bonds oc-
bly suggesting a causal relationship. However, the papercurs via enzyme-catalyzed glycosyltransfer reactions.
in this issue by Gibson and coworkers [3] on the retainingMuch is known about the structures and mechanisms
glycosyltransferase, trehalose-6-phosphate synthetaseof the degradative enzymes, glycosidases. Over 80 se-
(OtsA), also reveals a twin Rossman fold for this enzyme,quence-derived families have been identified to date,
showing clearly again that the fold does not dictateand structural representatives are available for approxi-
the mechanism. This provides a cautionary note on themately 50 of these; revealing a large number of different
overinterpretation of functional data from a predictedfolds. Mechanistically, they are divided into two classes.
protein fold (a major premise of structural genomics).The inverting glycosidases function via an acid/base-
The OtsA structural analysis also revealed a fascinat-catalyzed direct displacement mechanism, while the
ing mechanistic story. Despite the absence of any de-majority of the retaining glycosidases use a double-
tectable sequence similarity, the active site residuesdisplacement mechanism in which a covalent glycosyl-
of OtsA are essentially superimposable on those of aenzyme intermediate involving an active-site carboxylic
nonnucleotide sugar glycosyltransferase of the GT-Aacid is formed and hydrolyzed with acid/base catalytic
class, glycogen phosphorylase. This enzyme catalyzes theassistance. In an interesting variation found so far in
reversible phosphorolysis of glycogen with net retentionhexosaminidases from families 18, 20, and 56, the sub-
of configuration to produce glucose-1-phosphate. Onestrate’s own amide moiety functions as the nucleophile,and
of the more enigmatic aspects of the glycogen phos-reaction occurs via a bound oxazoline intermediate [1].
phorylase story has been its absolute requirement forBy contrast, much less is known about the enzymes
the coenzyme pyridoxal phosphate, which is covalentlyinvolved in glycoside synthesis, the sugar nucleotide-
bound at the active site as a Schiff’s base. A reason fordependent glycosyltransferases. Some 60 sequence-
derived families have been defined, but structures for this requirement has eluded explanation. Structural and
